Based on the recommendation of the Categorisation Commission, the Minister of Health of the SR Kamil Šaško decided to include a new medicine for patients with achondroplasia among the categorised medicines. The decision was published today on the website of the Ministry of Health. In this way, patients with this genetically-related disease will have access to the long-awaited advanced drug from 1 December 2025.
–I am pleased that at last Slovak patients with this genetic disease will have access to a modern drug and that Slovakia will be included in the countries where this modern treatment is available, stated Kamil Šaško, Minister for Health and added that "the area of medicine policy is very sensitive and we are doing our utmost in the ministry to ensure that every euro invested is spent for the benefit of the patient.
The negotiation of the CEC was preceded by the conclusion of a contract between the Ministry of Health of the Slovak Republic and the marketing authorisation holder for a medicinal product intended for the treatment of aquondroplasia, whose constructive approach in the negotiations the Ministry appreciates. The Categorisation Commission for Medicinal Products is composed of representatives of health insurance companies, the Ministry of Health of the Slovak Republic and experts. The final recommendation of the CEC serves as a basis for the decision of the Minister for Health to include the medicinal product in the list of categorised medicinal products.
Achondroplasia is a genetically-related disease characterised by typical manifestations such as, in particular, excessively low growth or disproportionately reduced limbs relative to the trunk.